New restrictions on opioids provide an excellent opportunity for pharmacists to raise awareness about dependence, naloxone and pain management, say stakeholders
Commencing Monday, 1 June 2020, the PBS listings for opioid medicines will change, the TGA has advised.
In response to concerns about deaths and hospitalisations due to prescription opioids, the PBAC recommended changes as part of a broader suite of measures, which are intended to support appropriate use of opioids, including education and awareness campaigns, changes to clinical guidelines and ongoing prescription and compliance monitoring.
Opioid medications will now be available in smaller quantities with no repeats for the treatment of non-chronic pain.
“To be eligible for treatment with opioids, patients will need to be unresponsive or intolerant, or have achieved inadequate relief of their acute pain, to maximum tolerated doses of non-opioid treatments,” the TGA says.
“Patients who require long-term treatment of chronic pain with opioids will still be able to access larger pack sizes and prescribers will be able to prescribe repeats where they meet the new restrictions requirements.
“For chronic pain, increased quantities and/or repeats may be authorised by Services Australia where the patient meets the restriction requirements.
“Increased quantities to extend treatment up to one month may be requested via telephone/electronic authority request, and up to three months’ supply (up to one-month quantity and up to two repeats) may be requested via an electronic/written authority request.
“To be eligible for treatment with high strength opioids such as morphine and fentanyl, patients will need to be unresponsive or intolerant, or have achieved inadequate relief of their acute pain, following maximum tolerated doses of other lower strength opioid treatments.
“These new arrangements apply to all PBS listings for opioid medications and therefore there will also be amendments to the tramadol and paracetamol/codeine restriction requirements.”
For pharmacists, this means that from 1 June 2020, some opioid listings will become Authority Required (Streamlined).
As a result, pharmacists will have to ensure any relevant dispensed scripts have a valid streamlined authority code, which needs to be valid at the date of prescribing.
“Pharmacists are also required to ensure prescribers have correctly requested increased quantities or repeats for chronic pain through telephone/electronic authority for up to one month’s treatment or electronic/written authority for up to three months’ treatment,” says the TGA.
Clinical Pharmacy Lecturer at La Trobe University, Pene Wood told the AJP that she thinks the change is “great – it’s something that I’ve advocated for”.
Dr Wood, who sees a lot of patients with pain management issues, often with complex needs who are taking opioids, in her work in a GP clinic, said that she sees a great deal of inappropriately prescribed fentanyl in particular.
“This is a good opportunity to have a conversation with [patients] and talk about why we need to change them off,” she said.
“The change creates awareness that these medicines aren’t designed to be used long-term, but in the short term for acute pain. If we’re only giving you 10, then after five days you shouldn’t need them any more.
“It also encourages people to go back to the doctor and seek feedback about the problem.”
She encouraged pharmacists to talk to patients who come in with scripts for opioids about the risks associated with their use, particularly in the long term.
She also encouraged them to discuss naloxone, saying that if the discussion is worded sensitively patients are more likely to be receptive to having the medicine on hand.
“Particularly if they’re on fentanyl, it’s something we can always offer to any patient, but in particular those on high-risk opioids, or opioids and sleeping tablets, or opioids and smoking, or with a respiratory condition,” she said.
“I have this conversation with most patients: I don’t use the word ‘overdose,’ I use the phrase, ‘opioid toxicity,’ and talk about how this medication can slow down your breathing, so that if you get the flu or use certain other medicines it could result in a bad outcome.
“I haven’t had one person knock it back yet.”
She also encouraged pharmacists to discuss naloxone with doctors – “We can ring them up, and say, ‘Have you thought about this?’”
Spokespeople for the Royal Australian College of General Practitioners also welcomed the TGA’s changes.
Chair of the RACGP Addiction Medicine network Dr Hester Wilson said that, “Limiting quantities and repeats is only one step towards reducing the harms that can result from opioids”.
“Unfortunately, I fear some people who have their opioid prescriptions limited will find it hard to give up and some may turn to black market alternatives.
“We need to be alert to that and government must ensure that there are enough treatment services available in as many locations as possible because substance use affects all communities
“I also think that we need to be much more proactive in helping patients with alcohol and other drug problems, including prescription drugs and illicit drugs.”
This includes GPs doing more to get naloxone into the hands of people who need it most, she said.
“Expanding access to opioid pharmacotherapy options such as methadone and buprenorphine is also really important.
“This can prove decisive in weaning people off opioid drugs. But again there is the factor of cost and some health professionals not having much knowledge or awareness of how beneficial this form of treatment can be.
“There is a certain stigma that still surrounds alcohol and other drug treatment and management and this needs to change. Problematic opioid use can affect anyone, it could be your mum or dad, a brother, a friend, a colleague, a neighbour – no one is immune.”
More information is available from the TGA here.